These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing, reported early 2004-002054-55 A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma not-yet-due
Completed, but no date, and reported results 2005-001474-27 A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma bad-data
Exempt, with results 2005-002338-36 A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours not-yet-due
Exempt 2005-002943-23 Ensayo clínico en fase I-II de Topotect (dexrazoxano) y dosis altas de etopósido en el tratamiento de pacientes adultos con tumores cerebrales sólidos, primarios o secundarios. not-yet-due
Not reported 2005-006157-24 A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma 2011-09-22 due-trials
Not reported 2006-000220-14 A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation 2007-05-30 due-trials
Not reported 2006-000910-19 A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma. 2011-03-24 due-trials
Reported results 2006-001886-40 A randomized, double-blind, placebo-controlled parallel group study to assess the safety and efficacy of a new oral formulation of 2-propyl pentanoic acid (2-PPA, PEAC minitablets) for the treatment o... 2008-09-16 due-trials
Exempt 2006-002850-31 APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemop... not-yet-due
Exempt, with results 2006-004345-42 A Phase I/II Clinical Trial of PXD101 in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas 2012-10-29 not-yet-due
Exempt, with results 2007-000241-35 A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy 2009-05-26 not-yet-due
Reported results 2007-000418-35 A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects with... 2008-08-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001396-11 A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas 2009-07-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005843-40 A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma 2014-10-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005865-67 An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carc... 2012-12-31 bad-data